VIMOVO

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG

Disponibbli minn:

ASTRA ZENECA ISRAEL LTD

Kodiċi ATC:

G02CC02

Għamla farmaċewtika:

TABLETS MODIFIED RELEASE

Rotta amministrattiva:

PER OS

Manifatturat minn:

ASTRA ZENECA AB., SWEDEN

Grupp terapewtiku:

NAPROXEN

Indikazzjonijiet terapewtiċi:

Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Data ta 'l-awtorizzazzjoni:

2011-12-01